Dr. Relkin is an internationally recognized expert on Alzheimer’s disease and related disorders. An American Board of Psychiatry and Neurology-certified neurologist, he graduated from Yale and earned MD and PhD degrees from New York’s Albert Einstein College of Medicine. Dr. Relkin is an Associate Professor of Neurology at the Weill Cornell Medical College and Founding Director of the Weill Cornell Memory Disorders Program. He has 20+ years of clinical trial experience, serving as principal investigator in over 20 therapeutic studies, including multi-center trials he designed. Over the past decade, Dr. Relkin pioneered studying naturally occurring human antibodies for treating Alzheimer’s. He led all three clinical trial phases of Intravenous Immunoglobulin as a potential Alzheimer’s treatment, including the pivotal National Institutes of Health (NIH) and Baxter co-sponsored study at 45 sites (US and Canada). Dr. Relkin, the author of numerous publications on neurodegenerative and traumatic disorders of the brain during the past 25 years, sits on editorial boards for three scientific journals. Additionally, he has been a reviewer for NIH and funding agencies in Europe and Australia and has been a long-standing Weill Cornell Institutional Review Board member. In 2012, he was elected to the Board of Directors of The American Federation for Aging Research.